The 7 major Chimeric Antigen Receptor (CAR) T-Cell Therapy markets reached a value of US$ 3,979.2 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach US$ 12,482.2 Million by 2035, ...

Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case ...

Engineering a patient's own T cells to express chimeric antigen receptors (CARs) has cured patients with cancer refractory to all treatments. Decades ago, as this modality was being developed, there ...

Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative ...

A patient has achieved over 18 years of remission from neuroblastoma, a type of nerve cell cancer, following treatment with chimeric antigen receptor (CAR) T cell therapy and without requiring any ...

Chimeric antigen receptor T-cells targeting the CD19 antigen have achieved impressive results in patients with relapsed/refractory (R/R) B-cell malignancies, leading to their approval in the European ...

CAS Key Laboratory of Nano-Bio Interface, Suzhou Key Laboratory of Functional Molecular Imaging Technology, Division of Nanobiomedicine and i-Lab, Suzhou Institute of Nano-Tech and Nano-Bionics, ...

aCenter for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA bDepartment of Pathology and Laboratory Medicine, University of Pennsylvania ...

Clinical outcomes from a prospective study of comprehensive genomic testing in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). This is an ASCO Meeting Abstract from the ...

IB-T101, a CD70-targeted chimeric antigen receptor therapy, is being studied for relapsed clear cell renal cell carcinoma ...

CAR-T cell therapy achieves 18-year survival milestone in cancer patient Innovative cancer treatment shows promise as ...